Mesa Laboratories, Inc. (MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2020, to shareholders of record at the close of business on May 29, 2020. Mesa is a global technology innovator committed to solving some of the most critical quality control challenges in the pharmaceutical, healthcare, industrial safety, environmental and food and beverage industries.
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Mesa Laboratories, Inc. (MLAB) (“Mesa”) today announced that it has commenced concurrent underwritten public offerings of 375,000 shares of its common stock and $150 million aggregate principal amount of its convertible senior notes due 2025 (the “notes”). In addition, Mesa expects to grant (a) the underwriters of the common stock offering a 30-day option to purchase up to 56,250 additional shares and (b) the underwriters of the notes offering a 13-day option to purchase up to $22.5 million aggregate principal amount of additional notes.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
It might be of some concern to shareholders to see the Mesa Laboratories, Inc. (NASDAQ:MLAB) share price down 15% in...
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Gary Owens became the CEO of Mesa Laboratories, Inc. (NASDAQ:MLAB) in 2017. This analysis aims first to contrast CEO...
Mesa Laboratories, Inc. (MLAB) (“Mesa”) today announced the pricing of concurrent underwritten public offerings of (a) 375,000 shares of its common stock at a public offering price of $210.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $78.8 million and (b) $150 million aggregate principal amount of its 1.375% convertible senior notes due 2025 (the “notes”). In addition, Mesa has granted (a) the underwriters of the common stock offering a 30-day option to purchase up to 56,250 additional shares and (b) the underwriters of the notes offering a 13-day option to purchase up to $22.5 million aggregate principal amount of additional notes. The offering of the shares is expected to result in approximately $73.9 million in net proceeds to Mesa after deducting underwriting discounts and commissions and other estimated offering expenses payable by Mesa (assuming no exercise of the underwriters’ option to purchase additional shares).
Mesa Labs (MLAB) delivered earnings and revenue surprises of 0.58% and -1.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Mesa Laboratories, Inc. (MLAB) today announced the election of Shannon Hall to its Board of Directors. Shannon previously led the Life Sciences business at Bio-Rad Laboratories. Ms. Hall’s election fills the open position created by the retirement of Robert Dwyer, a position he held for 14 years.
Mesa Laboratories (NASDAQ:MLAB) has had a rough three months with its share price down 20%. We, however decided to...
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gyros Protein Technologies AB, a Mesa Laboratories, Inc. (NASDAQ:MLAB) company, and pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, and the Jefferson Institute for Bioprocessing (JIB) at Thomas Jefferson University, a leading center of excellence providing advanced training to the bioprocessing industry, today announced that Gyrolab xPlore™ immunoassay system from Gyros Protein Technologies will be integrated into JIB’s curriculum. JIB’s industry training programs will also benefit from the technology to accelerate the generation of biologics for preclinical development.
LAKEWOOD, Colo., Nov. 06, 2019 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported record second quarter revenues and adjusted.
The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]
LAKEWOOD, Colo., Feb. 10, 2020 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, or “Mesa Labs”) today reported third quarter results for the three months ended December.
Today we are going to look at Mesa Laboratories, Inc. (NASDAQ:MLAB) to see whether it might be an attractive...
LAKEWOOD, Colo., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (MLAB) (we, us, our, “Mesa” or the “Company”), a diversified supplier of quality control instruments and consumables to highly regulated markets today announced the acquisition of Gyros Protein Technologies Holding AB (“GPT”). GPT is headquartered in Uppsala, Sweden and is a leading provider of Immunoassay and Peptide Synthesis solutions that accelerate the discovery, development and manufacturing of biotherapeutics. The acquisition deepens our commitment to biopharmaceutical quality control and will be the core of our new platform, Biopharmaceutical Development.